This Article Full Text (PDF) Other Versions of this Article: JVI.01357-07v1 82/13/6566    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Google Scholar Articles by Rulli, S. J. Articles by Rein, A. PubMed PubMed Citation Articles by Rulli, S. J., Jr. Articles by Rein, A.

 Previous Article  |  Next Article 

J. Virol. doi:10.1128/JVI.01357-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

INTERACTIONS OF MURINE APOBEC3 AND HUMAN APOBEC3G WITH MURINE LEUKEMIA VIRUSES

HIV Drug Resistance Program, National Cancer Institute-Frederick, and Basic Research Laboratory, and AIDS Vaccine Program, SAIC Frederick, Inc., Frederick, MD 21702-1201, and Department of Microbiology, Tufts University, Boston, MA 02111

^* To whom correspondence should be addressed. Email: rein{at}ncifcrf.gov.

	Abstract

APOBEC3 proteins are cytidine deaminases which help defend cells against retroviral infections. One antiviral mechanism involves deaminating dC residues in minus-strand DNA during reverse transcription, resulting in G:A mutations in the coding strand. We investigated the effects of mouse APOBEC3 (mA3) and human APOBEC3G (hA3G) upon Moloney murine leukemia virus (MLV). We find that mA3 inactivates MLV, but is significantly less effective against MLV than is hA3G. In contrast, mA3 is as potent against HIV-1 (lacking the protective Vif protein) as hA3G. The two APOBEC3 proteins are packaged to similar extents in MLV particles. Dose-response profiles imply that a single APOBEC3 molecule (or oligomer) is sufficient to inactivate an MLV particle. The inactivation of MLV by mA3 and hA3G is accompanied by relatively small reductions in the amount of viral DNA in infected cells. Although hA3G induces significant levels of G:A mutations in both MLV and HIV DNAs, and mA3 induces these mutations in HIV DNA, no such mutations were detected in DNA synthesized by MLV inactivated by mA3. Thus, MLV has apparently evolved to partially resist the antiviral effects of mA3, and to totally resist the ability of mA3 to induce G:A mutation in viral DNA. Unlike the resistance of HIV-1 and human T-cell leukemia virus type I to hA3G, the resistance of MLV to mA3 is not mediated by exclusion of the APOBEC from the virus particle. The nature of its resistance, and the mechanism of inactivation of MLV by mA3, are completely unknown.

This article has been cited by other articles:

• Santiago, M. L., Montano, M., Benitez, R., Messer, R. J., Yonemoto, W., Chesebro, B., Hasenkrug, K. J., Greene, W. C. (2008). Apobec3 Encodes Rfv3, a Gene Influencing Neutralizing Antibody Control of Retrovirus Infection. Science 321: 1343-1346 [Abstract] [Full Text]